SynDevRx Clinical Drug Candidate SDX-7320 Offsets Hyperglycemia Caused by PI3K/Akt/mTOR Cancer Therapies and Restores Insulin Sensitivity, Preclinical Studies Show

No Comments

CAMBRIDGE, Mass. – October 21, 2020 – SynDevRx, Inc., a clinical-stage oncology company, announces the completion of a series of preclinical studies demonstrating that its anti-cancer drug candidate, SDX-7320, inhibits PI3K/Akt inhibitor-induced hyperglycemia and subsequent hyperinsulinemia in normal mice and inhibits tumor growth in multiple models of HR+ breast cancer.

Read Press Release

New technology to be commercialized by Vesigen Therapeutics for targeted intracellular drug delivery

No Comments

A versatile vessel for next-gen therapeutics

Harvard University’s Office of Technology Development (OTD) and the Harvard T.H. Chan School of Public Health today announced the launch of Vesigen Therapeutics, a startup company that aims to overcome the challenge of delivering next-generation therapeutics, such as gene-editing complexes, RNA molecules, and other large proteins, to intracellular targets in specific tissues of interest.

Read Press Release

Arrakis, Roche team up on RNA-targeting drugs in $190M deal

No Comments

Elizabeth Radcliffe, Vice President of Finance and Strategy; Michael Gilman, Chief Executive Officer; Jennifer Petter, Founder and Chief Scientific Officer; Heather Lounsbury, Vice President of Business and Technical Operations; James Barsoum, Vice President of Research; Jacques Dumas, Senior Vice President of Drug Discovery (Arrakis Therapeutics)

Arrakis Therapeutics has been dodging pharma suitors since its early days, keeping its head down, building its RNA-targeting technology and “politely declining” advances “because we weren’t ready.”

Read Press Release

IFM Therapeutics Announces $55.5 Million Financing to Launch and Fund New Subsidiaries and Appointment of Dr. H. Martin Seidel as Chief Executive Officer

No Comments

 

 

 

 

 

  • IFM to launch IFM Quattro, along with new incubator, IFM Discovery, and up to two additional subsidiaries focused on select targets of the innate immune system
  • Financing is led by new investor Omega Funds, with participation from existing investors Atlas Venture and Abingworth
  • Dr. Gary D. Glick to transition to role of executive chairman

Read Press Release

Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System

No Comments

 

 

 

 

 

  • Acquisition of IFM Therapeutics subsidiary gives Novartis full rights to one clinical and two pre-clinical NLRP3 antagonist programs
  • NLRP3 inhibition offers novel approach to preventing chronic inflammation that drives serious disease
  • IFM to receive $310 million upfront, with up to $1.265 billion in milestones for a total of $1.575 billion

Read Press Release

Menu